Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 4/20 | 0.39 |
| ▸ | PIP5K1C | O60331 | 4/20 | 0.36 |
| ▸ | ITK | Q08881 | 4/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.35 |
| ▸ | CLK2 | P49760 | 3/20 | 0.35 |
| ▸ | CLK3 | P49761 | 3/20 | 0.35 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655338 | 0.86 | CLK2 (0.36) | VCPPIP5K1CITKDYRK1ACLK2 | |
| SCHEMBL13655335 | 0.82 | PIP5K1C (0.44) | PIP5K1CITKPARP1 | |
| SCHEMBL13655344 | 0.80 | CHEK1 (0.37) | PIP5K1CITKDYRK1ACLK2CLK3 | |
| SCHEMBL13655339 | 0.79 | CHEK1 (0.49) | DYRK1ACLK2CLK3 | |
| SCHEMBL13655343 | 0.70 | CHEK1 (0.45) | VCPPIP5K1CITKPARP1 | |
| SCHEMBL4165710 | 0.69 | CHEK1 (0.61) | VCPPIP5K1CITK | |
| SCHEMBL27688758 | 0.68 | CHEK1 (0.46) | ITK | |
| SCHEMBL5054104 | 0.66 | CHEK1 (0.62) | ITK | |
| SCHEMBL13655330 | 0.66 | CLK2 (0.39) | PIP5K1CDYRK1ACLK2CLK3 | |
| SCHEMBL27688756 | 0.66 | CHEK1 (0.46) | ITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | VCP 3106/4885PIP5K1C 1995/4885ITK 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.